T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer
Completed
- Conditions
- Prostate Cancer
- Registration Number
- NCT01376674
- Lead Sponsor
- University Hospital Tuebingen
- Brief Summary
Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner.
In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken at different time points before during and after standard radiotherapy in patients with localised prostate cancer. The overall activity of the T-cell-system as well as tumor-specific T-cell-response are evaluated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 22
Inclusion Criteria
- Localised prostate cancer (node negative)
- definitive radiotherapy
- informed consent
Exclusion Criteria
- medication including steroids or immunosuppressants
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method T-cell-immunity in time-course During and 3-6 months after radiotherapy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Radiation Oncology
🇩🇪Tuebingen, Germany